These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

489 related articles for article (PubMed ID: 29183891)

  • 1. TEM8/ANTXR1-Specific CAR T Cells as a Targeted Therapy for Triple-Negative Breast Cancer.
    Byrd TT; Fousek K; Pignata A; Szot C; Samaha H; Seaman S; Dobrolecki L; Salsman VS; Oo HZ; Bielamowicz K; Landi D; Rainusso N; Hicks J; Powell S; Baker ML; Wels WS; Koch J; Sorensen PH; Deneen B; Ellis MJ; Lewis MT; Hegde M; Fletcher BS; St Croix B; Ahmed N
    Cancer Res; 2018 Jan; 78(2):489-500. PubMed ID: 29183891
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TEM8/ANTXR1-specific CAR T cells mediate toxicity in vivo.
    Petrovic K; Robinson J; Whitworth K; Jinks E; Shaaban A; Lee SP
    PLoS One; 2019; 14(10):e0224015. PubMed ID: 31622431
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TEM8 marks neovasculogenic tumor-initiating cells in triple-negative breast cancer.
    Xu J; Yang X; Deng Q; Yang C; Wang D; Jiang G; Yao X; He X; Ding J; Qiang J; Tu J; Zhang R; Lei QY; Shao ZM; Bian X; Hu R; Zhang L; Liu S
    Nat Commun; 2021 Jul; 12(1):4413. PubMed ID: 34285210
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effective adoptive immunotherapy of triple-negative breast cancer by folate receptor-alpha redirected CAR T cells is influenced by surface antigen expression level.
    Song DG; Ye Q; Poussin M; Chacon JA; Figini M; Powell DJ
    J Hematol Oncol; 2016 Jul; 9(1):56. PubMed ID: 27439908
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intercellular Adhesion Molecule-1 as Target for CAR-T-Cell Therapy of Triple-Negative Breast Cancer.
    Wei H; Wang Z; Kuang Y; Wu Z; Zhao S; Zhang Z; Li H; Zheng M; Zhang N; Long C; Guo W; Nie C; Yang H; Tong A
    Front Immunol; 2020; 11():573823. PubMed ID: 33072116
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CAR T Cells Targeting the Tumor MUC1 Glycoprotein Reduce Triple-Negative Breast Cancer Growth.
    Zhou R; Yazdanifar M; Roy LD; Whilding LM; Gavrill A; Maher J; Mukherjee P
    Front Immunol; 2019; 10():1149. PubMed ID: 31178870
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor endothelial marker 8 expression in triple-negative breast cancer.
    Gutwein LG; Al-Quran SZ; Fernando S; Fletcher BS; Copeland EM; Grobmyer SR
    Anticancer Res; 2011 Oct; 31(10):3417-22. PubMed ID: 21965755
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting Stage-Specific Embryonic Antigen 4 (SSEA-4) in Triple Negative Breast Cancer by CAR T Cells Results in Unexpected on Target/off Tumor Toxicities in Mice.
    Pfeifer R; Al Rawashdeh W; Brauner J; Martinez-Osuna M; Lock D; Herbel C; Eckardt D; Assenmacher M; Bosio A; Hardt OT; Johnston ICD
    Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298141
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tissue factor as a new target for CAR-NK cell immunotherapy of triple-negative breast cancer.
    Hu Z
    Sci Rep; 2020 Feb; 10(1):2815. PubMed ID: 32071339
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ROR1-CAR T cells are effective against lung and breast cancer in advanced microphysiologic 3D tumor models.
    Wallstabe L; Göttlich C; Nelke LC; Kühnemundt J; Schwarz T; Nerreter T; Einsele H; Walles H; Dandekar G; Nietzer SL; Hudecek M
    JCI Insight; 2019 Sep; 4(18):. PubMed ID: 31415244
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel AXL chimeric antigen receptor endows T cells with anti-tumor effects against triple negative breast cancers.
    Wei J; Sun H; Zhang A; Wu X; Li Y; Liu J; Duan Y; Xiao F; Wang H; Lv M; Wang L; Wu C
    Cell Immunol; 2018 Sep; 331():49-58. PubMed ID: 29935762
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Engineered IL-7 Receptor Enhances the Therapeutic Effect of AXL-CAR-T Cells on Triple-Negative Breast Cancer.
    Zhao Z; Li Y; Liu W; Li X
    Biomed Res Int; 2020; 2020():4795171. PubMed ID: 31998790
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EGFR-specific CAR-T cells trigger cell lysis in EGFR-positive TNBC.
    Liu Y; Zhou Y; Huang KH; Li Y; Fang X; An L; Wang F; Chen Q; Zhang Y; Shi A; Yu S; Zhang J
    Aging (Albany NY); 2019 Dec; 11(23):11054-11072. PubMed ID: 31804974
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emerging CAR-T Cell Therapy for the Treatment of Triple-Negative Breast Cancer.
    Dees S; Ganesan R; Singh S; Grewal IS
    Mol Cancer Ther; 2020 Dec; 19(12):2409-2421. PubMed ID: 33087511
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human GUCY2C-Targeted Chimeric Antigen Receptor (CAR)-Expressing T Cells Eliminate Colorectal Cancer Metastases.
    Magee MS; Abraham TS; Baybutt TR; Flickinger JC; Ridge NA; Marszalowicz GP; Prajapati P; Hersperger AR; Waldman SA; Snook AE
    Cancer Immunol Res; 2018 May; 6(5):509-516. PubMed ID: 29615399
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Control of triple-negative breast cancer using ex vivo self-enriched, costimulated NKG2D CAR T cells.
    Han Y; Xie W; Song DG; Powell DJ
    J Hematol Oncol; 2018 Jul; 11(1):92. PubMed ID: 29980239
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DNA vaccine against tumor endothelial marker 8 inhibits tumor angiogenesis and growth.
    Ruan Z; Yang Z; Wang Y; Wang H; Chen Y; Shang X; Yang C; Guo S; Han J; Liang H; Wu Y
    J Immunother; 2009 Jun; 32(5):486-91. PubMed ID: 19609240
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The exosomes derived from CAR-T cell efficiently target mesothelin and reduce triple-negative breast cancer growth.
    Yang P; Cao X; Cai H; Feng P; Chen X; Zhu Y; Yang Y; An W; Yang Y; Jie J
    Cell Immunol; 2021 Feb; 360():104262. PubMed ID: 33373818
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chimeric antigen receptor-modified T Cells inhibit the growth and metastases of established tissue factor-positive tumors in NOG mice.
    Zhang Q; Wang H; Li H; Xu J; Tian K; Yang J; Lu Z; Zheng J
    Oncotarget; 2017 Feb; 8(6):9488-9499. PubMed ID: 28055955
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeted silencing of TEM8 suppresses non‑small cell lung cancer tumor growth via the ERK/Bcl‑2 signaling pathway.
    Gong Q; Deng J; Zhang L; Zhou C; Fu C; Wang X; Zhuang L
    Mol Med Rep; 2021 Aug; 24(2):. PubMed ID: 34165155
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.